November 27, 2022


You are Your Only Limit

Puma Biotechnology Studies Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2 min read

LOS ANGELES–(Business enterprise WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 1, 2022, the Payment Committee of Puma’s Board of Administrators accredited the grant of inducement limited inventory device awards covering 30,875 shares of Puma popular stock to six new non-executive staff members.

The awards had been granted underneath Puma’s 2017 Work Inducement Incentive Award Program, which was adopted on April 27, 2017 and provides for the granting of fairness awards to new staff of Puma. The restricted stock unit awards vest more than a 3-12 months time period, with a person-3rd of the shares fundamental every single award vesting on the to start with anniversary of the award’s vesting graduation day, July 1, 2022, and 1-sixth of the shares fundamental every award vesting on each and every 6-month anniversary of the vesting commencement day thereafter, subject to ongoing provider. The awards were granted as an inducement materials to the new workforce moving into into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a concentrate on the development and commercialization of progressive merchandise to greatly enhance cancer care. Puma in-licenses the world wide development and commercialization legal rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was accredited by the U.S. Meals and Drug Administration in 2017 for the prolonged adjuvant remedy of grownup clients with early stage HER2-overexpressed/amplified breast most cancers, subsequent adjuvant trastuzumab-based therapy, and is promoted in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also authorized by the Fda in mixture with capecitabine for the cure of adult individuals with superior or metastatic HER2-optimistic breast cancer who have gained two or additional prior anti-HER2-primarily based regimens in the metastatic location. NERLYNX was granted advertising and marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of grownup clients with early phase hormone receptor-good HER2-overexpressed/amplified breast most cancers and who are fewer than 1 yr from completion of prior adjuvant trastuzumab-based remedy. NERLYNX is a registered trademark of Puma Biotechnology, Inc. All rights reserved. | Newsphere by AF themes.